Literature DB >> 24398881

Altered intestinal microbiota and blood T cell phenotype are shared by patients with Crohn's disease and their unaffected siblings.

Charlotte R Hedin1, Neil E McCarthy2, Petra Louis3, Freda M Farquharson3, Sara McCartney4, Kirstin Taylor5, Natalie J Prescott5, Trevor Murrells6, Andrew J Stagg7, Kevin Whelan8, James O Lindsay9.   

Abstract

OBJECTIVE: Crohn's disease (CD) is associated with intestinal dysbiosis, altered blood T cell populations, elevated faecal calprotectin (FC) and increased intestinal permeability (IP). CD-associated features present in siblings (increased risk of CD) but not in healthy controls, provide insight into early CD pathogenesis. We aimed to (1) Delineate the genetic, immune and microbiological profile of patients with CD, their siblings and controls and (2) Determine which factors discriminate between groups.
DESIGN: Faecal microbiology was analysed by quantitative PCR targeting 16S ribosomal RNA, FC by ELISA, blood T cell phenotype by flow cytometry and IP by differential lactulose-rhamnose absorption in 22 patients with inactive CD, 21 of their healthy siblings and 25 controls. Subject's genotype relative risk was determined by Illumina Immuno BeadChip.
RESULTS: Strikingly, siblings shared aspects of intestinal dysbiosis with patients with CD (lower concentrations of Faecalibacterium prausnitzii (p=0.048), Clostridia cluster IV (p=0.003) and Roseburia spp. (p=0.09) compared with controls). As in CD, siblings demonstrated a predominance of memory T cells (p=0.002) and elevated naïve CD4 T cell β7 integrin expression (p=0.01) compared with controls. FC was elevated (>50 μg/g) in 8/21 (38%) siblings compared with 2/25 (8%) controls (p=0.028); whereas IP did not differ between siblings and controls. Discriminant function analysis determined that combinations of these factors significantly discriminated between groups (χ(2)=80.4, df=20, p<0.001). Siblings were separated from controls by immunological and microbiological variables.
CONCLUSIONS: Healthy siblings of patients with CD manifest immune and microbiological abnormalities associated with CD distinct from their genotype-related risk and provide an excellent model in which to investigate early CD pathogenesis. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  BACTERIAL PATHOGENESIS; CROHN'S DISEASE; GENOTYPE; T LYMPHOCYTES

Mesh:

Year:  2014        PMID: 24398881     DOI: 10.1136/gutjnl-2013-306226

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  55 in total

Review 1.  Host-microbiome interaction in Crohn's disease: A familiar or familial issue?

Authors:  Andrea Michielan; Renata D'Incà
Journal:  World J Gastrointest Pathophysiol       Date:  2015-11-15

Review 2.  Prognostic factors affecting outcomes in fistulating perianal Crohn's disease: a systematic review.

Authors:  G C Braithwaite; M J Lee; D Hind; S R Brown
Journal:  Tech Coloproctol       Date:  2017-06-20       Impact factor: 3.781

Review 3.  The microbiota in inflammatory bowel disease.

Authors:  Donal Sheehan; Carthage Moran; Fergus Shanahan
Journal:  J Gastroenterol       Date:  2015-03-26       Impact factor: 7.527

Review 4.  The intestinal microbiota: its role in health and disease.

Authors:  Luc Biedermann; Gerhard Rogler
Journal:  Eur J Pediatr       Date:  2015-01-07       Impact factor: 3.183

Review 5.  The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions.

Authors:  Stephen M Vindigni; Timothy L Zisman; David L Suskind; Christopher J Damman
Journal:  Therap Adv Gastroenterol       Date:  2016-04-19       Impact factor: 4.409

6.  Azathioprine therapy selectively ablates human Vδ2⁺ T cells in Crohn's disease.

Authors:  Neil E McCarthy; Charlotte R Hedin; Theodore J Sanders; Protima Amon; Inva Hoti; Ibrahim Ayada; Vidya Baji; Edward M Giles; Martha Wildemann; Zora Bashir; Kevin Whelan; Ian Sanderson; James O Lindsay; Andrew J Stagg
Journal:  J Clin Invest       Date:  2015-07-13       Impact factor: 14.808

7.  The gut microbiota of siblings offers insights into microbial pathogenesis of inflammatory bowel disease.

Authors:  Charlotte R Hedin; Christopher J van der Gast; Andrew J Stagg; James O Lindsay; Kevin Whelan
Journal:  Gut Microbes       Date:  2017-01-23

8.  Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease.

Authors:  Floris Imhann; Arnau Vich Vila; Marc Jan Bonder; Jingyuan Fu; Dirk Gevers; Marijn C Visschedijk; Lieke M Spekhorst; Rudi Alberts; Lude Franke; Hendrik M van Dullemen; Rinze W F Ter Steege; Curtis Huttenhower; Gerard Dijkstra; Ramnik J Xavier; Eleonora A M Festen; Cisca Wijmenga; Alexandra Zhernakova; Rinse K Weersma
Journal:  Gut       Date:  2016-10-08       Impact factor: 23.059

Review 9.  Current Understanding of Dysbiosis in Disease in Human and Animal Models.

Authors:  Arianna K DeGruttola; Daren Low; Atsushi Mizoguchi; Emiko Mizoguchi
Journal:  Inflamm Bowel Dis       Date:  2016-05       Impact factor: 5.325

Review 10.  Dietary Management in Pediatric Patients with Crohn's Disease.

Authors:  Luca Scarallo; Paolo Lionetti
Journal:  Nutrients       Date:  2021-05-11       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.